Abstract:Background: Hepatocellular carcinoma (HCC) is one of the most common and malignant tumors in the digestive tract. Tumor Suppressor Candidate 3 (TUSC3) is one subunit of the endoplasmic reticulum Oligosaccharyl transferase (OST) complex, which plays an important role in N-glycosylation during the protein folding process. However, the role of TUSC3 in the initiation and progression of HCC has not been mentioned yet. In the present study, we aim to investigate the effects of TUSC3 on the initiation and progression of HCC. Methods: Immunohistochemical assay and qRT-PCR were used to detect the expression of TUSC3 and lipase C hepatic type (LIPC) in HCC tissue and cells. Loss-of-function and gain-of-function were applied to detect the function of TUSC3 and LIPC in vivo and in vitro. Immunofluorescence assay and co-immunoprecipitation were used to detect the relationship between TUSC3 and LPC. Western blot was applied to detect the expression of epithelial-mesenchymal transition (EMT) markers and the Akt signaling pathway. Results: TUSC3 was aberrantly decreased in hepatocellular carcinoma tissues compared to the matched adjacent normal tissues, which resulted in bigger size of tumor (P = 0.001, Table 2), worse differentiation (P = 0.006, Table 2) and an advanced BCLC stage. Down-regulation of TUSC3 led to the enhanced proliferation and migration of hepatocellular carcinoma cells in vivo and vitro, whereas the opposite effect could be observed in the TUSC3-overexpression group. The analysis of TUSC3 microarray showed that LIPC, a glycoprotein primarily synthesized and secreted by hepatocytes, was a downstream target of TUSC3, and it negatively modulated the development of HCC. The morphological changes in HCC cells indicated that TUSC3 regulated the epithelial-mesenchymal transition (EMT). Mechanistically, TUSC3 inhibited EMT progression through the LIPC/AKT axis. Conclusion: Down-regulation of TUSC3 promotes EMT progression by activating AKT signaling via targeting LIPC in HCC, which is probably the possible mechanism driving TUSC3-deficient hepatocellular carcinoma cells toward a malignant phenotype.

The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition

Expression of TIG3 in the hepatocellular carcinoma and its inhibitory effect

Expression of TIGIT/CD155 and Correlations with Clinical Pathological Features in Human Hepatocellular Carcinoma

Knockdown of TIGAR by RNA Interference Induces Apoptosis and Autophagy in HepG2 Hepatocellular Carcinoma Cells.

Transactivation of the TIEG1 Confers Growth Inhibition of Transforming Growth Factor-Β-susceptible Hepatocellular Carcinoma Cells.

Neurotrophin3 promotes hepatocellular carcinoma apoptosis through the JNK and P38 MAPK pathways

Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis

Expression and Inhibitory Role of TIMP-3 in Hepatocellular Carcinoma.

Immune landscape of hepatocellular carcinoma: The central role of TP53-inducible glycolysis and apoptosis regulator

TIG2 in primary hepatocellular carcinoma and its significance

Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma

Triiodothyronine (T3) suppresses hepatic tumorigenesis and development by inhibiting the phosphorylation of ERK

Gamma-Tocotrienol Inhibits Proliferation and Growth of HSD17B4-Overexpressing HepG2 Liver Cancer Cells

ATF3 Inhibits the Tumorigenesis and Progression of Hepatocellular Carcinoma Cells Via Upregulation of CYR61 Expression

TIGAR Enhanced Free Ca2+ Concentration in Hepatocellular Carcinoma Cells to Accelerate the Sustained Proliferation and Drug Resistance

Downregulation Of Inhibitor Of Growth 3 Is Correlated With Tumorigenesis And Progression Of Hepatocellular Carcinoma

Tazarotene-induced Gene 1 Induces Melanoma Cell Death by Triggering Endoplasmic Reticulum Stress Response

TRAIL promotes hepatocellular carcinoma apoptosis and inhibits proliferation and migration via interacting with IER3

TLX3 Repressed SNAI1-induced Epithelial-Mesenchymal Transition by Directly Constraining STAT3 Phosphorylation and Functionally Sensitized 5-FU Chemotherapy in Hepatocellular Carcinoma

Reduced N-acetylglucosaminyltransferase III Expression Via Smad3 and Erk Signaling in TGF-β1-induced HCC EMT Model.

TGM3 Promotes Epithelial-Mesenchymal Transition and Hepatocellular Carcinogenesis and Predicts Poor Prognosis for Patients after Curative Resection.